Industry Perspectives

SCIEX launches novus V55 triple quadrupole mass spectrometer

The novus V55 system delivers high-speed quantitative performance with improved energy efficiency and a compact footprint.
Brought to you bySCIEX
| 2 min read
The novus V55 System

credit: sciex

Register for free to listen to this article
Listen with Speechify
0:00
2:00

Marlborough, MA. June 1st, 2026 SCIEX, a Danaher company and leader in life science analytical technologies, has launched the novus V55 system a next-generation triple quadrupole mass spectrometer designed for the realities of high-pressure, results-driven labs. The system provides exceptional sensitivity and accelerated output, in a smaller footprint and with improved energy efficiency when compared to the SCIEX 5500+ system. This quantitative solution expands testing capabilities across pesticide and food analysis, pharmaceutical impurities, bioanalysis, PFAS testing, and additional applications.

The novus V55 system is built for business and real-world impact. Key features include:

  • aeMRM (accelerated MRM) can acquire up to 1,000 MRMs per second, which increases sample throughput, expands testing capabilities, and maintains quantitative accuracy.
  • New SCIEX OS 5.0 software introduces new features including:
    • Central Metrics Tracker allows for tracking of performance and assay level metrics.
    • Central Monitoring shows instrument status across the fleet.
    • Reporter Template Creator easily creates customized reports.
    • AI enabled "helpme" function answers feature and functionality questions quickly using a natural language interface.
    • AI enabled Calculated Columns creates custom calculations for columns with natural language.
  • OptiFlow source, built off the same technology trusted by thousands of customers world-wide, upholds the robustness and sensitivity synonymous with SCIEX systems.
  • 35 percent smaller footprint makes it the most compact triple quad in its class without compromising sensitivity or quantitative performance.
  • 40 percent reduction in both energy consumption and laboratory cooling requirements helps to lower operational energy costs.
  • Compatibility with any LC system, LIMS support, and 21 CFR Part 11 maintains compliance and operational confidence.

“Analytical labs are being asked to deliver more insight with less time, space, and energy. With the novus V55 system, we have applied decades of innovation to ensure robustness and sensitivity, while enhancing performance and execution. This new generational instrument will help enable our customers to drive their business forward,” said Chris Lock, Vice President Global Research and Development at SCIEX.

This 5th generation system builds on a proven legacy in nominal mass. In 1981, SCIEX launched the TAGA 6000, the first commercial triple quadrupole. Since then, the triple quadrupoles have evolved with the API III, then the API 3000, and then to the SCIEX Triple Quad series starting with SCIEX Triple Quad 5500 system. SCIEX also developed QTRAP technology which combined triple quad and linear ion trap technology for the first time.

Learn more about the novus V55 system at https://sciex.com/products/mass-spectrometers/triple-quad-systems/novus-v55-system.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Crystal Girod, Senior Product Manager at Beckman Coulter Life Sciences, featured in a “Tell Us What You Know” graphic titled “Making Lab Automation More Accessible,” alongside the Beckman Coulter Life Sciences logo.
Explore how advances in liquid handling are making automation more accessible, flexible, and practical for modern labs.
Puzzle pieces spelling “DATA” alongside connected icons representing data analysis, storage, and reporting.
Earlier insight into analytical data can help laboratories recognize emerging trends and maintain method performance over time.
3D illustration of an antibody-drug conjugate with cytotoxic payloads attached to an antibody.
Explore how integrated cell-based assays reveal the mechanisms that drive antibody-drug conjugate activity and inform candidate selection.